Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01099228 · ClinicalTrials.gov registry record · NA
Combination Targeted Radiotherapy in Neuroendocrine Tumors
A NA study, sponsored by David Bushnell.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01099228: Completed NA study, sponsored by David Bushnell.
NCT01099228 is a NA study that has completed, run by David Bushnell. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01099228, a NA study, has completed, sponsored by David Bushnell.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary aim of this project is to determine, what fraction of individuals with neuroendocrine tumors would show substantially improved tumor dosimetry with combined agent therapy compared to "best" single agent therapy and determine the magnitude of the potential tumor radiation dose increase.
Primary Outcome
Determine the patient specific bone marrow, kidney and tumor dosimetry results for each subject from the 2 groups will be used to calculate the optimal combination of administered activities for 131I-MIBG plus 90Y-DOTATOC (group 1) 131I-MIBG plus 177Lu-DOTATATE (group 2) and the resultant dose delivery to tumor from each combination
Interventions
- OTHER 131-I MIBG and 111-In pentetreotide
- OTHER 131-I MIBG and In-111 DOTATATE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-09 |
| Est. Completion | 2015-07 |
| Phase | NA |
What the finished NCT01099228 record still lists
NCT01099228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which 131-I MIBG and 111-In pentetreotide is the first listed.
NCT01099228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01099228 about?
NCT01099228 is a clinical study titled "Combination Targeted Radiotherapy in Neuroendocrine Tumors". The primary aim of this project is to determine, what fraction of individuals with neuroendocrine tumors would show substantially improved tumor dosimetry with combined agent therapy compared to "best" single agent therapy and determine the magnitude of the potential tumor radiation dose increase.
What is the current status of trial NCT01099228?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2006-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01099228?
The interventions under investigation include: 131-I MIBG and 111-In pentetreotide (OTHER), 131-I MIBG and In-111 DOTATATE (OTHER).
Who is sponsoring clinical trial NCT01099228?
This trial is sponsored by David Bushnell, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01099228's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia